Nektar(US:NKTR) Globenewswire·2026-03-17 19:49Core Viewpoint - A class action lawsuit has been filed against Nektar Therapeutics and certain officers for alleged violations of federal securities laws during the Class Period from February 26, 2025, to December 15, 2025, seeking damages for affected investors [1]. Company Overview - Nektar Therapeutics is a biopharmaceutical company focused on developing therapies that modulate the immune system for treating autoimmune disorders [4]. - The company's lead product candidate is rezpegaldesleukin (REZPEG or NKTR-358), aimed at treating conditions such as alopecia areata [4]. Clinical Trial Information - In March 2024, Nektar initiated the Phase 2b REZOLVE-AA trial to evaluate rezpegaldesleukin in 94 patients with severe-to-very severe alopecia areata [5]. - The trial's enrollment criteria included specific diagnostic and treatment history requirements to ensure patient eligibility [5]. - By February 2025, Nektar announced the completion of target enrollment for the REZOLVE-AA trial, asserting compliance with applicable protocols [6]. Allegations and Misconduct - The Complaint alleges that during the Class Period, Nektar's executives made materially false and misleading statements regarding the company's operations and compliance, particularly concerning the REZOLVE-AA trial [7]. - Specific allegations include failure to disclose that enrollment did not adhere to protocol standards, which could negatively impact trial results and misrepresent the trial's integrity [7]. Disclosure of Trial Results - On December 16, 2025, Nektar released topline results from the REZOLVE-AA trial, indicating that the trial did not achieve statistical significance due to the inclusion of ineligible patients [8]. - Following this announcement, Nektar's stock price dropped by $4.14 per share, or 7.77%, closing at $49.16 per share [9].